| Drug NDC: | 64578-0060 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Medi-chord |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Homeopathic Liquid |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Energetix Corporation |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Liquid |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | ACETIC ACID - 18 [hp_X]/59.1mL ALUMINUM - 18 [hp_X]/59.1mL ARCTIUM LAPPA ROOT - 4 [hp_X]/59.1mL ASPIRIN - 18 [hp_X]/59.1mL ATROPA BELLADONNA - 12 [hp_X]/59.1mL BENZENE - 12 [hp_X]/59.1mL CHLORAMPHENICOL - 18 [hp_X]/59.1mL CHLORPROMAZINE - 18 [hp_X]/59.1mL CORTICOTROPIN HUMAN - 18 [hp_X]/59.1mL CORTISONE ACETATE - 18 [hp_X]/59.1mL Load more... ELYMUS REPENS ROOT - 4 [hp_X]/59.1mL ESTRONE - 18 [hp_X]/59.1mL FRANGULA PURSHIANA BARK - 4 [hp_X]/59.1mL GLYCYRRHIZA GLABRA - 4 [hp_X]/59.1mL KEROSENE - 18 [hp_X]/59.1mL LEAD - 15 [hp_X]/59.1mL LYCOPODIUM CLAVATUM SPORE - 12 [hp_X]/59.1mL NITRIC ACID - 12 [hp_X]/59.1mL PHENACETIN - 18 [hp_X]/59.1mL PHENYL SALICYLATE - 18 [hp_X]/59.1mL PHOSPHORIC ACID - 12 [hp_X]/59.1mL PHYTOLACCA AMERICANA ROOT - 4 [hp_X]/59.1mL PORK LIVER - 9 [hp_X]/59.1mL POTASSIUM IODIDE - 12 [hp_X]/59.1mL SARSAPARILLA - 4 [hp_X]/59.1mL STRYCHNOS NUX-VOMICA SEED - 12 [hp_X]/59.1mL SUS SCROFA ADRENAL GLAND - 9 [hp_X]/59.1mL THYROID, UNSPECIFIED - 9 [hp_X]/59.1mL TRIFOLIUM PRATENSE FLOWER - 4 [hp_X]/59.1mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 21 Sep, 2017 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 25 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Energetix Corporation |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000000160 N0000008836 M0001335 N0000175722 N0000175578 N0000008832 N0000175480 N0000175479 N0000175746 M0016525 N0000185371 N0000185375 N0000175629 N0000184306 M0000728 M0006342 M0016962 N0000185001 M0516536 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | Q40Q9N063P CPD4NFA903 597E9BI3Z3 R16CO5Y76E WQZ3G9PF0H J64922108F 66974FR9Q1 U42B7VYA4P 63KF469V7T 883WKN7W8X Load more... 3IXW0F6P8W 2DI9HA706A 4VBP01X99F 2788Z9758H 1C89KKC04E 2P299V784P C88X29Y479 411VRN1TV4 ER0CTH01H9 28A37T47QO E4GA8884NN 11E6VI8VEG 6EC706HI7F 1C4QK22F9J 2H1576D5WG 269XH13919 398IYQ16YV 0B4FDL9I6P 4JS0838828 |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class MOA: | Cyclooxygenase Inhibitors [MoA] |
| Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`. | |
| Pharmacologic Class EPC: | Nonsteroidal Anti-inflammatory Drug [EPC] Platelet Aggregation Inhibitor [EPC] Amphenicol-class Antibacterial [EPC] Phenothiazine [EPC] Non-Standardized Food Allergenic Extract [EPC] Non-Standardized Plant Allergenic Extract [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Decreased Prostaglandin Production [PE] Decreased Platelet Aggregation [PE] Increased Histamine Release [PE] Cell-mediated Immunity [PE] Increased IgG Production [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Anti-Inflammatory Agents, Non-Steroidal [CS] Phenothiazines [CS] Allergens [CS] Dietary Proteins [CS] Plant Proteins [CS] Seed Storage Proteins [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Allergens [CS] Amphenicol-class Antibacterial [EPC] Amphenicols [EXT] Anti-Inflammatory Agents Non-Steroidal [CS] Cell-mediated Immunity [PE] Corticosteroid Hormone Receptor Agonists [MoA] Corticosteroid [EPC] Cyclooxygenase Inhibitors [MoA] Decreased Platelet Aggregation [PE] Decreased Prostaglandin Production [PE] Dietary Proteins [CS] Increased Histamine Release [PE] Increased IgG Production [PE] Non-Standardized Food Allergenic Extract [EPC] Non-Standardized Plant Allergenic Extract [EPC] Nonsteroidal Anti-inflammatory Drug [EPC] Phenothiazine [EPC] Phenothiazines [CS] Plant Proteins [CS] Platelet Aggregation Inhibitor [EPC] Seed Storage Proteins [CS] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 64578-0060-1 | 59.1 mL in 1 BOTTLE, DROPPER (64578-0060-1) | 21 Sep, 2017 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.